XML 46 R40.htm IDEA: XBRL DOCUMENT v3.24.3
Collaboration Agreements, License Agreement and Revenues - Drug Product Revenue - Summary of Drug Product Revenue (Detail) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Jun. 30, 2023
Mar. 31, 2023
Sep. 30, 2024
Sep. 30, 2023
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Drug product revenue recognized $ 46,333 $ 40,134     $ 152,877 $ 120,614
Drug Product Revenue, Net [Member]            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Drug product revenue recognized (262) 1,320     24,954 17,701
Drug Product Revenue, Net [Member] | Japan [Member]            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Drug product revenue recognized     $ 14,400 $ 1,700    
Drug Product Revenue, Net [Member] | Astellas Agreement [Member]            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Drug product revenue recognized 300       700  
Drug Product Revenue, Net [Member] | Astellas Agreement [Member] | Japan [Member]            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Drug product revenue recognized (1,355) 695     (3,926) 16,236
Drug Product Revenue, Net [Member] | Astellas Agreement [Member] | Europe [Member]            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Drug product revenue recognized 1,093 625     3,209 1,465
Drug Product Revenue, Net [Member] | AstraZeneca Agreements [Member] | U.S. [Member]            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Drug product revenue recognized $ 0 $ 0     $ 25,671 $ 0